---
title: "Allogene Therapeutics, Inc. (ALLO.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ALLO.US/overview.md"
symbol: "ALLO.US"
name: "Allogene Therapeutics, Inc."
parent: "https://longbridge.com/en/quote/ALLO.US.md"
datetime: "2026-04-15T09:28:54.199Z"
locales:
  - [en](https://longbridge.com/en/quote/ALLO.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ALLO.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ALLO.US/overview.md)
---

# Allogene Therapeutics, Inc. (ALLO.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Address | 210 East Grand Avenue, South San Francisco, California, United States |
| Website | [allogene.com](https://allogene.com) |

## Company Profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL).

## Key Executives

| Name | Title |
|------|-------|
| Arie S. Belldegrun | Co-Founder & Executive Chairman |
| David D. Chang | Co-Founder, President, CEO & Director |
| Joshua A. Kazam | Co-Founder & Director |
| Zachary J. Roberts | Executive VP of Research & Development and Chief Medical Officer |
| Geoffrey M. Parker | Executive VP & CFO |
| Franz Bernhard Humer | Lead Independent Director |
| Owen N. Witte | Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| Pfizer Venture Investments LLC | 9.04% | 2025-12-31 |
| TPG Capital, L.P. | 7.68% | 2025-12-31 |
| BlackRock, Inc. | 7.25% | 2025-12-31 |
| Citadel Advisors LLC | 4.97% | 2025-12-31 |
| The Vanguard Group, Inc. | 3.80% | 2025-12-31 |
| PRIMECAP Management Company | 3.34% | 2025-12-31 |
| David D. Chang | 2.44% | 2026-03-16 |
| Arie S. Belldegrun | 2.40% | 2026-02-02 |
| Patient Square Capital, LP | 2.04% | 2025-12-31 |
| Geode Capital Management, LLC | 1.61% | 2025-12-31 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Pharmaceuticals | 22000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Allogene Therapeutics, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Pharmaceuticals",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| United States | 22000 | 100% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**